Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HMGCR | P04035 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6991990 | 0.79 | HMGCR (0.48) | ALDH1A1TDP1HMGCRCHRM1TBXA2R | |
| SCHEMBL10033928 | 0.79 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2TDP1HMGCRCHRM1 | |
| SCHEMBL27492431 | 0.77 | KDM4E (0.30) | — | |
| SCHEMBL22455355 | 0.77 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2TDP1 | |
| Ammonia Solution, Strong SCHEMBL25278018 | 0.75 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL3502605 | 0.73 | TRPA1 (0.32) | TRPA1 | |
| SCHEMBL3822875 | 0.72 | TRPA1 (0.36) | ALDH1A1SMN1; SMN2TRPA1 | |
| SCHEMBL16790656 | 0.70 | KDM4E (0.37) | ALDH1A1ADRA1A | |
| SCHEMBL13560183 | 0.69 | — | — | |
| SCHEMBL869584 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193228-B2 | Substituted imidazole as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20100022598-A1 | Substituted inmidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME LLC | 2010-01-28 | — | — | US | disclosed |
| EP-2091937-A2 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | Merck & Co., Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008051406-A2 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | MERCK & CO., INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022598-A1 | Substituted inmidazoles as bombesin receptor subtype-3 modulators | BRS3, INSR, INSRR | ALDH1A1 4786/4885SMN1; SMN2 2399/4885TDP1 3540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.